Abstract
Signaling events involving angiotensin IV (ANG IV)-mediated pulmonary artery endothelial cell (PAEC) proliferation were examined. ANG IV significantly increased upstream phosphatidylinositide (PI) 3-kinase (PI3K), PI-dependent kinase-1 (PDK-1), extracellular signal-related kinases (ERK1/2), and protein kinase B-alpha/Akt (PKB-alpha) activities, as well as downstream p70 ribosomal S6 kinase (p70S6K) activities and/or phosphorylation of these proteins. ANG IV also significantly increased 5-bromo-2'-deoxy-uridine incorporation into newly synthesized DNA in a concentration- and time-dependent manner. Pretreatment of cells with wortmannin and LY-294002, inhibitors of PI3K, or rapamycin, an inhibitor of the mammalian target of rapamycin kinase and p70S6K, diminished the ANG IV-mediated activation of PDK-1 and PKB-alpha as well as phosphorylation of p70S6K. Although an inhibitor of mitogen-activated protein kinase kinase, PD-98059, but not rapamycin, blocked ANG IV-induced phosphorylation of ERK1/2, both PD-98059 and rapamycin independently caused partial reduction in ANG IV-mediated cell proliferation. However, simultaneous treatment with PD-98059 and rapamycin resulted in total inhibition of ANG IV-induced cell proliferation. These results demonstrate that ANG IV-induced DNA synthesis is regulated in a coordinated fashion involving multiple signaling modules in PAEC.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
3-Phosphoinositide-Dependent Protein Kinases
-
Androstadienes / pharmacology
-
Angiotensin II / analogs & derivatives*
-
Angiotensin II / pharmacology*
-
Animals
-
Anti-Bacterial Agents / pharmacology
-
Cell Division / drug effects
-
Cell Division / physiology
-
Cells, Cultured
-
Endothelium / cytology
-
Endothelium / metabolism
-
Enzyme Activation / drug effects
-
Enzyme Inhibitors / pharmacology
-
Flavonoids / pharmacology
-
Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors
-
Mitogen-Activated Protein Kinase 1 / metabolism
-
Mitogen-Activated Protein Kinase 3
-
Mitogen-Activated Protein Kinases / antagonists & inhibitors
-
Mitogen-Activated Protein Kinases / metabolism
-
Phosphatidylinositol 3-Kinases / metabolism
-
Phosphoinositide-3 Kinase Inhibitors
-
Phosphorylation
-
Protein Serine-Threonine Kinases / metabolism
-
Proto-Oncogene Proteins c-akt
-
Proto-Oncogene Proteins*
-
Pulmonary Artery / cytology*
-
Pulmonary Artery / enzymology*
-
Ribosomal Protein S6 Kinases / metabolism
-
Signal Transduction / physiology*
-
Sirolimus / pharmacology
-
Swine
-
Wortmannin
Substances
-
Androstadienes
-
Anti-Bacterial Agents
-
Enzyme Inhibitors
-
Flavonoids
-
Phosphoinositide-3 Kinase Inhibitors
-
Proto-Oncogene Proteins
-
Angiotensin II
-
angiotensin II, des-Asp(1)-des-Arg(2)-Ile(5)-
-
3-Phosphoinositide-Dependent Protein Kinases
-
Protein Serine-Threonine Kinases
-
Proto-Oncogene Proteins c-akt
-
Ribosomal Protein S6 Kinases
-
Mitogen-Activated Protein Kinase 1
-
Mitogen-Activated Protein Kinase 3
-
Mitogen-Activated Protein Kinases
-
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
-
Sirolimus
-
Wortmannin